3 Profitable Stocks That Concern Us

Even if a company is profitable, it doesn’t always mean it’s a great investment. Some struggle to maintain growth, face looming threats, or fail to reinvest wisely, limiting their future potential.

Not all profitable companies are created equal, and that’s why we built StockStory - to help you find the ones that truly shine bright. Keeping that in mind, here are three profitable companies to steer clear of and a few better alternatives.

Movado (MOV)

Trailing 12-Month GAAP Operating Margin: 3.1%

With its watches displayed in 20 museums around the world, Movado (NYSE:MOV) is a watchmaking company with a portfolio of watch brands and accessories.

Why Do We Think MOV Will Underperform?

1. Annual revenue declines of 4.3% over the last two years indicate problems with its market positioning
2. Projected sales growth of 1.2% for the next 12 months suggests sluggish demand
3. Waning returns on capital imply its previous profit engines are losing steam

At $17.46 per share, Movado trades at 0.6x forward price-to-sales. To fully understand why you should be careful with MOV, check out our full research report (it’s free for active Edge members).

NVR (NVR)

Trailing 12-Month GAAP Operating Margin: 17.4%

Known for its unique land acquisition strategy, NVR (NYSE:NVR) is a respected homebuilder and mortgage company in the United States.

Why Does NVR Worry Us?

1. New orders were hard to come by as its average backlog growth of 1.3% over the past two years underwhelmed
2. Estimated sales decline of 6.9% for the next 12 months implies a challenging demand environment
3. Waning returns on capital imply its previous profit engines are losing steam

NVR’s stock price of $7,556 implies a valuation ratio of 17.5x forward P/E. Check out our free in-depth research report to learn more about why NVR doesn’t pass our bar.

Corcept (CORT)

Trailing 12-Month GAAP Operating Margin: 14.2%

Focusing on the powerful stress hormone that affects everything from metabolism to immune function, Corcept Therapeutics (NASDAQ:CORT) develops and markets medications that modulate cortisol to treat endocrine disorders, cancer, and neurological diseases.

Why Are We Wary of CORT?

1. Day-to-day expenses have swelled relative to revenue over the last five years as its adjusted operating margin fell by 16.9 percentage points
2. Earnings per share fell by 2.8% annually over the last five years while its revenue grew, showing its incremental sales were much less profitable
3. Eroding returns on capital suggest its historical profit centers are aging

Corcept is trading at $76.44 per share, or 74.3x forward P/E. Read our free research report to see why you should think twice about including CORT in your portfolio.

Stocks We Like More

Donald Trump’s April 2025 "Liberation Day" tariffs sent markets into a tailspin, but stocks have since rebounded strongly, proving that knee-jerk reactions often create the best buying opportunities.

The smart money is already positioning for the next leg up. Don’t miss out on the recovery - check out our Top 9 Market-Beating Stocks. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025).

Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-small-cap company Exlservice (+354% five-year return). Find your next big winner with StockStory today for free. Find your next big winner with StockStory today. Find your next big winner with StockStory today

StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here.